[Federal Register Volume 73, Number 152 (Wednesday, August 6, 2008)]
[Notices]
[Page 45784]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E8-17961]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on May 28, 2008, Chattem 
Chemicals Inc., 3801 St. Elmo Avenue, Building 18, Chattanooga, 
Tennessee 37409, made application by renewal to the Drug Enforcement 
Administration (DEA) as a bulk manufacturer of the basic classes of 
controlled substances listed in schedules I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
4-Methoxyamphetamine (7411).................  I
Difenoxin (9168)............................  I
Amphetamine (1100)..........................  II
Methamphetamine (1105)......................  II
Methylphenidate (1724)......................  II
Pentobarbital (2270)........................  II
Codeine (9050)..............................  II
Oxycodone (9143)............................  II
Hydrocodone (9193)..........................  II
Meperidine (9230)...........................  II
Dextropropoxyphene, bulk (non-dosage forms)   II
 (9273).
Morphine (9300).............................  II
Thebaine (9333).............................  II
Noroxymorphone (9668).......................  II
Alfentanil (9737)...........................  II
Sufentanil (9740)...........................  II
Fentanyl (9801).............................  II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
in bulk for distribution to its customers.
    Any other such applicant, and any person who is presently 
registered with DEA to manufacture such substances, may file comments 
or objections to the issuance of the proposed registration pursuant to 
21 CFR 1301.33(a).
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than October 6, 2008.

    Dated: July 29, 2008.
 Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
 [FR Doc. E8-17961 Filed 8-5-08; 8:45 am]
BILLING CODE 4410-09-P